RxDoctor Payments Data

Thomas Chacko, MD

Allergy · Alpharetta, GANPI 1356443089

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (48.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Novartis at 48.4% of the total.

$63,145in general payments, 2019–2025

Across 411 payments — averaging $153.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$31K
  • Regeneron Healthcare Solutions, Inc.$11K
  • Genentech, Inc.$7K
  • Sanofi$6K
  • ARS Pharmaceuticals Operations, Inc.$2K
  • Optinose US, Inc.$2K
  • plus $4K from 22 others

What the payments were for

  • Consulting fees$30,58348%
  • Speaking & faculty fees$15,50725%
  • Travel & lodging$5,4629%
  • Food & beverage$11,51518%
  • Education$780%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$194,485
Medicare patients
258
Services billed
11,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab45$193,217
XolairOmalizumab39$108,281
Breo ElliptaFluticasone/Vilanterol28$11,295
Azelastine Hcl114$2,543
Epinephrine14$1,902
Wixela InhubFluticasone Propion/Salmeterol18$1,257
Ipratropium Bromide38$1,099
Fluticasone Propionate143$994
Albuterol Sulfate HfaAlbuterol Sulfate34$646
Famotidine69$466
Montelukast Sodium58$318
Pantoprazole Sodium25$207
Triamcinolone Acetonide11$145
Methylprednisolone19$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech, Inc.Xolair$6,605$108,28139 claims
GSKBreo Ellipta$816$11,29528 claims
Hikma Pharmaceuticals USAEpinephrine$45$1,90214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other allergy in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →